Ximena Jordan Bruno

Ximena Jordan Bruno

Auto-generated profile, based on publicly available information

Ximena Jordan Bruno

Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
XBXimena Jordan Bruno
Ximena Jordan Bruno
IKInsu Koh
Insu Koh
PLPamela Lutsey
Pamela Lutsey
RWRobert F. Walker
Robert F. Walker
NRNicholas S. Roetker
Nicholas S. Roetker
NZNeil A. Zakai
Neil A. Zakai
Thirty to seventy percent of all venous thromboembolism (VTE) events are associated with hospitalization. The absolute and relative risks during and after hospitalization are poorly characterized. Quantify the absolute rate and relative risk of VTE during and up to 3 months after medical and surgical hospitalizations. We conducted an observational cohort study between 2010 and 2016 of patients cared for by the University of Vermont (UVM) Health Network's primary care population. Cox proportional hazard models with hospitalization modeled as a time‐varying covariate were used to estimate VTE risk. Over 4.3 years of follow‐up, 55 220 hospitalizations (156 per 1000 person‐years) and 713 first venous thromboembolism events (2.0 per 1000 person‐years) occurred. Among individuals not recently hospitalized, the rate of venous thromboembolism was 1.4 per 1000 person‐years and 71.8 per 1000 person‐years during hospitalization. During the first, second, and third months after discharge, the rates of venous thromboembolism were 35.1, 11.3, and 5.2 per 1000 person‐years, respectively. Relative to those not recently hospitalized, the age‐ and sex‐adjusted HRs of venous thromboembolism were 38.0 (95% CI 28.0, 51.5) during hospitalization, and 18.4 (95% CI 15.0, 22.6), 6.3 (95% CI 4.3, 9.0), and 3.0 (95% CI 1.7, 5.4) during the first, second, and third months after discharge, respectively. Stratified by medical versus surgical services the rates were similar. Hospitalization and up to 3 months after discharge were strongly associated with increased venous thromboembolism risk. These data quantify this risk for use in future studies.

1 October 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
SMSindhu Malapati
Sindhu Malapati
DIDame Idossa
Dame Idossa
SSSunny R.K. Singh
Sunny R.K. Singh
ZWZihan Wei
Zihan Wei
LKLauren Kiel
Lauren Kiel
NDNarjust Duma
Narjust Duma
Oncology trainee/early-career faculty survey shows inadequate parental leave/lactation policies #parentpenalty

4 March 2022 in JCO Global Oncology
Verified
Journal Article
Open access
CBCarolina Bernabe-Ramirez
Carolina Bernabe-Ramirez
AVAna I. Velazquez
Ana I. Velazquez
COCoral Olazagasti
Coral Olazagasti
CBCristiane Decat Bergerot
Cristiane Decat Bergerot
PBPaulo Gustavo Bergerot
Paulo Gustavo Bergerot
HGHOLA COVID-19 Study Group
HOLA COVID-19 Study Group
PURPOSE: The HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer.METHODS: This international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice.RESULTS: A total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care.CONCLUSION: The COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.

5 August 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
SKShaurya Khanna
Shaurya Khanna
SWSean Woo
Sean Woo
SSSandra P. Susanibar-Adaniya
Sandra P. Susanibar-Adaniya
GWGary E. Weissman
Gary E. Weissman
MBMeghan L. Blair
Meghan L. Blair
CGCarmen E Guerra
Carmen E Guerra
PURPOSE: Approximately 8% of the US population speaks primary languages other than English. Limited English proficiency (LEP) contributes to under-representation of Hispanic patients in oncology clinical trials. Although certified translation services exist, they are time-consuming and costly. Artificial intelligence (AI)–generated translations of informed consent forms (ICFs) could provide low-cost alternatives, but data on accuracy and safety remain limited. We evaluated language equivalence of English-to-Spanish translations for three oncology clinical trial ICFs using two general-purpose AI translation tools (DeepL Pro and ChatGPT-4o) and a medically trained AI translation tool (Med_English2Spanish) compared with certified translations. METHODS: Translational equivalence was assessed using a five-point Likert scale on five domains: Semantic, Idiomatic, Experiential, Conceptual, and Safety. Two native Spanish-speaking bilingual board-certified physicians independently scored each translation. Weighted Cohen's kappa determined inter-rater reliability, and the two-sample t-test compared AI-generated and certified translations. RESULTS: Weighted Cohen's kappa (0.95, 95% CI 0.85 to 0.97) exhibited high inter-rater agreement. Certified translations exhibited the highest equivalence (mean = 4.99, SD = 0.02). ChatGPT-4o similarly demonstrated high equivalence (mean = 4.89, SD = 0.17). DeepL Pro scored well (mean = 4.43, SD = 0.07) but lower than certified translation ( P < 0.001). Med_English2Spanish demonstrated the lowest degree of equivalence (mean = 3.32, SD = 0.40) compared with certified translations ( P < 0.001). CONCLUSION: Low-cost AI translations of ICFs exhibited variable language equivalence compared with certified translations across several domains. ChatGPT-4o scored nearly equivalent across domains in translating procedural trial information. While AI-generated translations are currently not suitable for clinical deployment without human review, this exploratory study supports further analysis of AI translation tools for reducing language barriers to LEP population enrollment.

1 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Benjamin BleibergBenjamin Bleiberg
Benjamin Bleiberg
JSJackson Steinkamp
Jackson Steinkamp
XBXimena Jordan Bruno
Ximena Jordan Bruno
333 Background: Family history screening for malignancies informs the need for genetic testing of cancer patients and their families. Associations between heritable mutations and solid malignancies are well-established, but germline contributions to hematologic malignancies may be of similar importance. For instance, the pooled risk of a group of heritable transcription factor mutations including RUNX1, GATA2, and CEBPA may play a role in up to 15% of new cases of leukemia. Standard of care for new patient visits in malignant hematology clinics should involve thorough family screening like that of solid malignancies more classically associated with heredity. Methods: All patients presenting to an academic hospital system's outpatient GI, breast, and leukemia clinics for new patient visits in a 3-month period were identified accounting for 706 participants (breast n=258 (36.5%), GI n=303 (42.9%), leukemia n=145 (20.5%)). Retrospective chart review was completed by EMR report, which aggregated data from individuals identified by their cancer diagnosis. Groups were compared along the following variables: percentage with completed 1st degree (parents and siblings) family history of malignancy screening, percentage with completed 2nd degree (grandparents, aunts, and uncles) family history screening. Chi-squared significance testing was completed to identify significant (p<0.05) differences in screening, which was considered completed if entered in the searchable summary information of the patient’s chart. Results: Patients presenting for new patient visits in breast (77.1%) cancer clinic had significantly higher rates of 1st degree family history of malignancy screening than those presenting with new diagnoses of leukemia (62.1%). The comparison of 1st degree screening for GI (71.6%) cancer patients and leukemia patients was not significant. Rates of 2nd degree family history screening were significantly higher for patients with new diagnoses of breast (61.6%) and GI (37.0%) cancers as compared to those with leukemia (24.8%). The combined cohort of GI and breast cancer patients had significantly greater rates of 1st (74.2%) and 2nd degree (48.4%) family history screening than patients with new diagnosis of leukemia. Conclusions: There is growing appreciation of heritable germline contributors to leukemia pathogenesis. However, there remains a deficit in clearly documented, easily referenced family history screening for malignancies in patients with new diagnoses of leukemia when compared to patients with new diagnoses of classically heritable solid malignancies.